## 5 Experimental Study
### Medical Data Analyses
#### 5.1.1 Rheumatoid Arthritis Database Results  
Out of the total of 76 patients with rheumatoid arthritis, 80.3% (n = 61) were women and 19.7% (n = 15) were men. The age of the patients ranged between 19 and 81 years old. At the time of inclusion in the study, the distribution of RA patients by gender and the biological therapy is given in Table 2.  
During the study period, 7 patients (9.21%), 5 women and 2 men, switched to another biological treatment, as follows:  
-  A patient switched from Simponi (Golimumab) to Roacentra (Tocilizumab);  
-  A patient switched from Mabthera (Rituximab) to Roacentra (Tocilizumab);  
-  A patient switched from Orencia (Abatacept) to Benepali (biosimilar Etanercept);  
-  A patient switched from Cimzia (Certolizumab) to Roacentra (Tocilizumab);  
-  A patient switched from Humira (Adalimumab) to Roacentra (Tocilizumab);  
-  A patient switched from Humira (Adalimumab) to Enbrel (Etanercept);  
-  A patient switched from Enbrel (Etanercept) to Humira (Adalimumab). At the end of the study, the distribution of patients by gender and the biological therapy is presented in Table 3. \begin{table}
\begin{tabular}{c c c c c} \hline
**Trade Name** & \begin{tabular}{c} **International** \\ **Nonproprietary Name** \\ \end{tabular} & **Patients (\%)** & \
\begin{tabular}{c} **Women** \\ **(nr., \%)** \\ \end{tabular} &
\begin{tabular}{c} **Men** \\ **(nr., \%)** \\ \end{tabular} \\ \hline BENEPALI & Etanercept (biosimilar) & n = 3 (3.95) & n = 3 (3.95) & n = 0 (0) \\ \hline CIMZIA & Certolizumab & n = 3 (3.95) & n = 3 (3.95) & n = 0 (0) \\ \hline ENBREL & Etanercept (original) & n = 13 (17.11) & n = 8 (10.53) & n = 5 (6.58) \\ \hline HUMIRA & Adalimumab & n = 14 (18.42) & n = 12 (15.79) & n = 2 (2.63) \\ \hline MABTHERA & Rituximab & n = 20 (26.32) & n = 18 (23.68) & n = 2 (2.63) \\ \hline ORENCIA & Abatacept & n = 2 (2.63) & n = 2 (2.67) & n = 0 (0) \\ \hline REMICADE & Infiximab (biosimilar) & n = 1 (1.31) & n = 0 (0) & n = 1 (1.31) \\ \hline REMSIMA & Infiximab (original) & n = 1 (1.31) & n = 1 (1.31) & n = 0 (0) \\ \hline ROACTEMRA & Tocilizumab & n = 16 (21.05) & n = 12 (15.79) & n = 4 (5.26) \\ \hline SIMPONI & Golimumab & n = 3 (3.95) & n = 2 (2.63) & n = 1 (1.31) \\ \hline Total & & n = 76 (100) & n = 61 (80.3) & n = 15 (19.7) \\ \hline \end{tabular} n = number of cases expressed as absolute value (percentage of the total number of cases).  
\end{table} 
Table 2: Distribution of RA patients by gender and the biological therapy followed at the time of inclusion in the study. \begin{table}
\begin{tabular}{c c c c c} \hline
**Trade Name** & \begin{tabular}{c} **International** \\ **Nonproprietary Name** \\ \end{tabular} & **Patients (\%)** & \
\begin{tabular}{c} **Women** \\ **(nr., \%)** \\ \end{tabular} &
\begin{tabular}{c} **Men** \\ **(nr., \%)** \\ \end{tabular} \\ \hline BENEPALI & Etanercept (biosimilar) & n = 4 (5.26) & n = 4 (5.26) & n = 0 (0) \\ \hline CIMZIA & Certolizumab & n = 2 (2.63) & n = 2 (2.63) & n = 0 (0) \\ \hline ENBREL & Etanercept (original) & n = 13 (17.11) & n = 8 (10.53) & n = 5 (6.58) \\ \hline HUMIRA & Adalimumab & n = 13 (17.11) & n = 11 (14.47) & n = 2 (2.63) \\ \hline MABTHERA & Rituximab & n = 19 (25) & n = 17 (22.37) & n = 2 (2.63) \\ \hline ORENCIA & Abatacept & n = 1 (1.31) & n = 1 (1.31) & n = 0 (0) \\ \hline REMICADE & Infiximab (biosimilar) & n = 1 (1.31) & n = 0 (0) & n = 1 (1.31) \\ \hline REMSIMA & Infiximab (original) & n = 1 (1.31) & n = 1 (1.31) & n = 0 (0) \\ \hline ROACTEMRA & Tocilizumab & n = 20 (26.32) & n = 16 (21.05) & n = 4 (5.26) \\ \hline SIMPONI & Golimumab & n = 2 (2.63) & n = 1 (1.31) & n = 1 (1.31) \\ \hline Total & & n = 76 (100) & n = 61 (80) & n = 15 (20) \\ \hline \end{tabular} n = number of cases expressed as absolute value (percentage of the total number of cases).  
\end{table} 
Table 3: Distribution of RA patients by gender and the biological therapy followed at the end of the study.